Hiroki Kitamoto

Hiroki Kitamoto

Auto-generated profile, based on publicly available information

Hiroki Kitamoto

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Departments of Gastroenterology and Hepatology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2020 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SBShigeki Bamba
Shigeki Bamba
RSRyosuke Sakemi
Ryosuke Sakemi
TFToshimitsu Fujii
Toshimitsu Fujii
TTTeruyuki Takeda
Teruyuki Takeda
SFShin Fujioka
Shin Fujioka
THToshifumi Hibi
Toshifumi Hibi

30 October 2018 in Intestinal Research
Verified
Journal Article
Open access
PDF file
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
TFToshimitsu Fujii
Toshimitsu Fujii
SBShigeki Bamba
Shigeki Bamba
MOMaiko Ogawa
Maiko Ogawa
TKTaku Kobayashi
Taku Kobayashi
THToshifumi Hibi
Toshifumi Hibi
The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients. IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians' global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation. A total of 429 IBD (378 ulcerative colitis, 51 Crohn's disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78-3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81-3.11; P=0.172]). Based on the physicians' global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months' observation period. The overall eradication rate was 84.0%-comparable to previous reports in non-IBD patients. H. pylori eradication therapy does not alter the short-term disease activity of IBD.

27 January 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
KHK Hamada
K Hamada
HKH Kitamoto
H Kitamoto
MOM Okabe
M Okabe
YHY Honzawa
Y Honzawa
SYS Yamamoto
S Yamamoto
Click on the article title to read more.


1 January 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
PDF file
MFMasashi Fukushima
Masashi Fukushima
HKHiroki Kitamoto
Hiroki Kitamoto
TITetsuro Inokuma
Tetsuro Inokuma
YIYukihiro Imai
Yukihiro Imai

1 October 2019 in The Lancet
Verified
Journal Article
Closed access
HKHiroki Kitamoto
Hiroki Kitamoto
SISatoko Inoue
Satoko Inoue
KOKoji Okamoto
Koji Okamoto
TITetsuro Inokuma
Tetsuro Inokuma